Access cutting-edge smoking cessation treatment through this clinical trial at a research site in Baltimore. Study-provided care at no cost to qualified participants.
Access smoking cessation specialists in Baltimore at no cost
This study follows strict safety protocols and ethical guidelines
All study-related smoking cessation treatment provided free
This is a multi-site, double-blind, randomized clinical trial of the 5-HT2A receptor agonist psilocybin for smoking cessation. Four sites with experience in conducting psilocybin research will be involved in this trial: Johns Hopkins University (JHU), the University of Alabama at Birmingham (UAB), and New York University (NYU). The proposed study will treat 66 participants (22 at each site), randomized to receive either: 1) oral psilocybin (30 mg in session 1 and either 30 mg or 40 mg in session
Sponsor: Johns Hopkins University
Check if you qualify for this smoking cessation clinical trial in Baltimore, MD
If you're searching for smoking cessation treatment options in Baltimore, MD, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Baltimore research site is actively enrolling participants for this clinical trial. You'll receive care from experienced smoking cessation specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.